RIGL — Rigel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $882.62m
- $826.53m
- $294.28m
Brief: Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For Gavreto® (Pralsetinib)
Licensing Agreement For "Olutasidenib", An Acute Myeloid Leukemia Drug
Brief: Rigel Expands Relationship With Kissei To Include Rezlidhia (Olutasidenib) In Japan, The Republic Of Korea And Taiwan
Rigel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rigel Pharmaceuticals Q2 EPS USD -0.06 Vs. IBES Estimate USD -0.29
Brief: Rigel Announces Reverse Stock Split
Brief: Rigel Pharmaceuticals Completes Transfer Of Gavreto New Drug Application
Rigel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Rigel Pharmaceuticals Q1 EPS USD -0.05 Vs. IBES Estimate USD -0.03
Rigel Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Rigel Pharmaceuticals Enters Amendment To Credit & Security Deal To Extend Maturity For Term Loans
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Brief: Rigel Pharmaceuticals Announces Appointment Of Lisa Rojkjaer, M.D. As Chief Medical Officer
Rigel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rigel Reports Fourth Quarter Results, Provides Business Update
Rigel Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Elf Beauty, Moderna, Zscaler
U.S. STOCKS ON THE MOVE-J.B. Hunt, Synopsys, DoorDash
U.S. STOCKS ON THE MOVE-Wayfair Inc, Remitly Global, Monopar Therapeutics